Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07843264 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PPI Dosing Per CYP2C19 Genotype

Name: PPI Dosing Per CYP2C19 Genotype — clinical trial record (NCT07843264)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorUniversity of Florida

Started2026-10

View on ClinicalTrials.gov ↗

University of Florida

325 trials monitored

See 23 trials at risk

This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.

Trial Details

NCT Number	NCT07843264
Lead Sponsor	University of Florida
Conditions	Gastroesophageal Reflux Disease With Esophagitis
Enrollment	200 participants
Start Date	2026-10
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-28